Delving into the Latest Updates on Amantadine/Oseltamivir/Ribavirin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Amantadine/ribavirine/oseltamivir, Oseltamivir/amantadine/ribavirin, Oseltamivir/ribavirin/amantadine

+ [3]

Target

DRDs x IMPDH x Influenza A neuraminidase x NMDA receptor x RNAP x RNGTT

Action

agonists, inhibitors, antagonists

Mechanism

DRDs agonists(Dopamine receptors agonists), IMPDH inhibitors(Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)

+ [3]

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

Influenza A virus infection

Originator Organization

National Institutes of Health

Active Organization-

Inactive Organization

Adamas Pharmaceuticals LLC

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC8H12N4O5

InChIKeyIWUCXVSUMQZMFG-AFCXAGJDSA-N

CAS Registry36791-04-5

View All Structures (3)

Seasonal influenza is responsible for many hospitalizations and deaths each year, despite effective antiviral treatments. Some individuals have medical conditions such as heart or lung diseases that make them particularly at risk of severe influenza infections that may result in hospitalization or death. Oseltamivir (Tamiflu) is used most often to treat flu, but there are still many hospitalizations, complications, and deaths even with treatment. This study evaluated the use of combination antivirals (amantadine, oseltamivir, and ribavirin) compared to oseltamivir alone in the treatment of influenza in an at-risk population.

Start Date01 Sep 2010

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

NCT00979251

/ CompletedPhase 2

A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects

This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.

Start Date01 Sep 2009

Sponsor / Collaborator

Adamas Pharmaceuticals LLC

NCT00867139

/ CompletedPhase 1/2IIT

A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients

The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD

Start Date01 Mar 2009

Sponsor / Collaborator

Fred Hutchinson Cancer Research Center

100 Clinical Results associated with Amantadine/Oseltamivir/Ribavirin

Login to view more data

100 Translational Medicine associated with Amantadine/Oseltamivir/Ribavirin

Login to view more data

100 Patents (Medical) associated with Amantadine/Oseltamivir/Ribavirin

Login to view more data

27

Literatures (Medical) associated with Amantadine/Oseltamivir/Ribavirin

01 Jan 2024·Trends in Hearing

The Impact of Hearing Aids on Listening Effort and Listening-Related Fatigue - Investigations in a Virtual Realistic Listening Environment

Article

Author: Heeren, J. ; Wagener, K. ; Gordon, C. ; Schulte, M. ; Meis, M. ; Latzel, M. ; Mirkovic, B. ; Crowhen, D. ; Blümer, M.

Participation in complex listening situations such as group conversations in noisy environments sets high demands on the auditory system and on cognitive processing. Reports of hearing-impaired people indicate that strenuous listening situations occurring throughout the day lead to feelings of fatigue at the end of the day. The aim of the present study was to develop a suitable test sequence to evoke and measure listening effort (LE) and listening-related fatigue (LRF), and, to evaluate the influence of hearing aid use on both dimensions in mild to moderately hearing-impaired participants. The chosen approach aims to reconstruct a representative acoustic day (Time Compressed Acoustic Day [TCAD]) by means of an eight-part hearing-test sequence with a total duration of approximately 2½ h. For this purpose, the hearing test sequence combined four different listening tasks with five different acoustic scenarios and was presented to the 20 test subjects using virtual acoustics in an open field measurement in aided and unaided conditions. Besides subjective ratings of LE and LRF, behavioral measures (response accuracy, reaction times), and an attention test (d2-R) were performed prior to and after the TCAD. Furthermore, stress hormones were evaluated by taking salivary samples. Subjective ratings of LRF increased throughout the test sequence. This effect was observed to be higher when testing unaided. In three of the eight listening tests, the aided condition led to significantly faster reaction times/response accuracies than in the unaided condition. In the d2-R test, an interaction in processing speed between time (pre- vs. post-TCAD) and provision (unaided vs. aided) was found suggesting an influence of hearing aid provision on LRF. A comparison of the averaged subjective ratings at the beginning and end of the TCAD shows a significant increase in LRF for both conditions. At the end of the TCAD, subjective fatigue was significantly lower when wearing hearing aids. The analysis of stress hormones did not reveal significant effects.

01 Apr 2017·The FASEB JournalQ2 · BIOLOGY

Adiponectin association with T‐cadherin protects against neointima proliferation and atherosclerosis

Q2 · BIOLOGY

Article

Author: Maeda, Norikazu ; Masuda, Shigeki ; Sekimoto, Ryohei ; Mori, Takuya ; Ranscht, Barbara ; Kita, Shunbun ; Nishizawa, Hitoshi ; Obata, Yoshinari ; Shimomura, Iichiro ; Fukuda, Shiro ; Fujishima, Yuya ; Yamaoka, Masaya ; Funahashi, Tohru ; Matsuda, Keisuke

Adiponectin, an adipocyte-derived protein abundant in the circulation, is thought to be protective against atherosclerosis. However, it is not fully understood how the association of adiponectin with vascular cells and its antiatherogenic effect are connected. In this study, T-cadherin was essential for accumulation of adiponectin in the neointima and atherosclerotic plaque lesions, and the adiponectin-T-cadherin association protected against vascular injury. In the apolipoprotein E-knockout (ApoE-KO) mice, adiponectin and T-cadherin colocalized on endothelial cells and synthetic smooth muscle cells in the aortic intima. Notably, aortic adiponectin protein disappeared in T-cadherin/ApoE double-knockout (Tcad/ApoE-DKO) mice with significant elevation of blood adiponectin concentration. Furthermore, in Tcad/ApoE-DKO mice, carotid artery ligation resulted in a significant increase of neointimal thickness compared with ApoE-KO mice. Finally, on a high-cholesterol diet, Tcad/ApoE-DKO mice increased atherosclerotic plaque formation, despite a 5-fold increase in plasma adiponectin level compared with that in ApoE-KO mice. In vitro, knockdown of T-cadherin from human aortic smooth muscle cells (HASMCs) with synthetic phenotype significantly reduced adiponectin accumulation on HASMCs and negated the inhibitory effect of adiponectin on proinflammatory change. Collective evidence showed that adiponectin accumulates in the vasculature via T-cadherin, and the adiponectin-T-cadherin association plays a protective role against neointimal and atherosclerotic plaque formations.-Fujishima, Y., Maeda, N., Matsuda, K., Masuda, S., Mori, T., Fukuda, S., Sekimoto, R., Yamaoka, M., Obata, Y., Kita, S., Nishizawa, H., Funahashi, T., Ranscht, B., Shimomura, I. Adiponectin association with T-cadherin protects against neointima proliferation and atherosclerosis.

01 Aug 2014·Global Spine Journal

Traumatic Dissection of Four Brain-Supplying Arteries without Neurologic Deficit

Author: Powerski, Maciej ; Heining, Sandro ; Nolte, Christian H. ; Ertel, Wolfgang ; Pröscholdt, Florian

Study Design Case report and review of the literature. Objectives Case report of a traumatic dissection of all major brain-supplying arteries resulting from a horseback-riding accident. Overview of the literature on diagnostic and therapeutic recommendations. Methods Case presentation. For the discussion, handpicked articles and PubMed database research with the keywords “dissection,” “vertebral artery,” “spine trauma,” “computed tomography,” “magnetic resonance imaging,” and “angiography” were used. Results Despite high-energy induced acute lesion of all four cervical arteries, this 45-year-old patient did not demonstrate signs of microemboli nor suffer from stroke. Conclusion In case of high-energy trauma of the head and/or the neck, emergency physicians must consider traumatic cervical artery dissection (TCAD). Thus, emergency care algorithms should routinely include computed tomography angiography and magnetic resonance imaging. Although the incidence of TCAD-induced stroke is low, antiplatelet therapy is recommended in the presence of TCAD.

100 Deals associated with Amantadine/Oseltamivir/Ribavirin

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza A virus infection	Phase 2	United States	Adamas Pharmaceuticals LLC	01 Sep 2009
Influenza A virus infection	Phase 2	Canada	Adamas Pharmaceuticals LLC	01 Sep 2009
Influenza A virus infection	Phase 2	Australia	Adamas Pharmaceuticals LLC	01 Sep 2009
Influenza A virus infection	Phase 2	Singapore	Adamas Pharmaceuticals LLC	01 Sep 2009
Influenza A virus infection	Phase 2	Netherlands	Adamas Pharmaceuticals LLC	01 Sep 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01227967 (IRC003, CTgov)	Phase 2	Influenza, Human	881	Amantadine, Ribavirin, Oseltamivir (Combination Therapy)	lqbbazwvao(awgbzxoroy) = avmomnpbqc zjwchvofkk (nxbbwqxiiv, ntgkwsdiww - mxmjxdozno) View more	-	11 Jul 2017
				oseltamivir (Oseltamivir Monotherapy)	lqbbazwvao(awgbzxoroy) = udodvhkzod zjwchvofkk (nxbbwqxiiv, abzndokafx - kaoytxszou) View more
NCT00867139 (CTgov)	Phase 1/2	Influenza A virus infection	7	oseltamivir+ribavirin+amantadine (TCAD)	eeccqxjpmo(mfgklxyhmv) = hgsvfriltq qzgtzipqie (qysukvmwiw, sdqnjgwrth - nvvvrlrggm) View more	-	04 Jun 2013
				Inihibitor (Neuraminidase Inihibitor Monotherapy)	eeccqxjpmo(mfgklxyhmv) = lvfogvahkf qzgtzipqie (qysukvmwiw, jfvbklxowq - hamhpvtfiw) View more